Header Logo

Connection

Yuki Kageyama to Antineoplastic Agents, Hormonal

Back to Details
This is a "connection" page, showing publications Yuki Kageyama has written about Antineoplastic Agents, Hormonal.
Yuki Kageyama
Connection Strength
0.273
Antineoplastic Agents, Hormonal
  1. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer. Recent Pat Anticancer Drug Discov. 2007 Nov; 2(3):203-11.
    View in: PubMed
    Score: 0.258
  2. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int. 2006 Jun; 97(6):1184-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.